767 related articles for article (PubMed ID: 29943666)
1. Recurrent Glioblastoma Treated with Recombinant Poliovirus.
Desjardins A; Gromeier M; Herndon JE; Beaubier N; Bolognesi DP; Friedman AH; Friedman HS; McSherry F; Muscat AM; Nair S; Peters KB; Randazzo D; Sampson JH; Vlahovic G; Harrison WT; McLendon RE; Ashley D; Bigner DD
N Engl J Med; 2018 Jul; 379(2):150-161. PubMed ID: 29943666
[TBL] [Abstract][Full Text] [Related]
2. Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.
Thompson EM; Landi D; Brown MC; Friedman HS; McLendon R; Herndon JE; Buckley E; Bolognesi DP; Lipp E; Schroeder K; Becher OJ; Friedman AH; McKay Z; Walter A; Threatt S; Jaggers D; Desjardins A; Gromeier M; Bigner DD; Ashley DM
Lancet Child Adolesc Health; 2023 Jul; 7(7):471-478. PubMed ID: 37004712
[TBL] [Abstract][Full Text] [Related]
3. Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.
Chandramohan V; Bryant JD; Piao H; Keir ST; Lipp ES; Lefaivre M; Perkinson K; Bigner DD; Gromeier M; McLendon RE
Arch Pathol Lab Med; 2017 Dec; 141(12):1697-1704. PubMed ID: 28829151
[TBL] [Abstract][Full Text] [Related]
4. Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.
Walton RW; Brown MC; Sacco MT; Gromeier M
J Virol; 2018 Oct; 92(19):. PubMed ID: 29997212
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.
Beasley GM; Nair SK; Farrow NE; Landa K; Selim MA; Wiggs CA; Jung SH; Bigner DD; True Kelly A; Gromeier M; Salama AK
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33875611
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Poliovirus for Cancer Immunotherapy.
Gromeier M; Nair SK
Annu Rev Med; 2018 Jan; 69():289-299. PubMed ID: 29414253
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.
Brown MC; Gromeier M
Curr Opin Virol; 2015 Aug; 13():81-5. PubMed ID: 26083317
[TBL] [Abstract][Full Text] [Related]
8. Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS.
Yang Y; Brown MC; Zhang G; Stevenson K; Mohme M; Kornahrens R; Bigner DD; Ashley DM; López GY; Gromeier M
Neuro Oncol; 2023 Sep; 25(9):1631-1643. PubMed ID: 36864784
[TBL] [Abstract][Full Text] [Related]
9. The Practical Consideration of Poliovirus as an Oncolytic Virotherapy.
Denniston E; Crewdson H; Rucinsky N; Stegman A; Remenar D; Moio K; Clark B; Higginbotham A; Keffer R; Brammer S; Horzempa J
Am J Virol; 2016; 5(1):1-7. PubMed ID: 28203321
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.
Brown MC; Holl EK; Boczkowski D; Dobrikova E; Mosaheb M; Chandramohan V; Bigner DD; Gromeier M; Nair SK
Sci Transl Med; 2017 Sep; 9(408):. PubMed ID: 28931654
[TBL] [Abstract][Full Text] [Related]
11. The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study.
Barkley A; Butler E; Park C; Friedman A; Landi D; Ashley DM; Bigner D; Bernstock JD; Friedman GK; Johnston JM; Thompson EM
J Neurosurg Pediatr; 2024 Apr; 33(4):359-366. PubMed ID: 38215438
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.
Kicielinski KP; Chiocca EA; Yu JS; Gill GM; Coffey M; Markert JM
Mol Ther; 2014 May; 22(5):1056-62. PubMed ID: 24553100
[TBL] [Abstract][Full Text] [Related]
13. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.
Holl EK; Brown MC; Boczkowski D; McNamara MA; George DJ; Bigner DD; Gromeier M; Nair SK
Oncotarget; 2016 Nov; 7(48):79828-79841. PubMed ID: 27806313
[TBL] [Abstract][Full Text] [Related]
14. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.
Hayes RL; Koslow M; Hiesiger EM; Hymes KB; Hochster HS; Moore EJ; Pierz DM; Chen DK; Budzilovich GN; Ransohoff J
Cancer; 1995 Sep; 76(5):840-52. PubMed ID: 8625188
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
Forsyth P; Roldán G; George D; Wallace C; Palmer CA; Morris D; Cairncross G; Matthews MV; Markert J; Gillespie Y; Coffey M; Thompson B; Hamilton M
Mol Ther; 2008 Mar; 16(3):627-32. PubMed ID: 18253152
[TBL] [Abstract][Full Text] [Related]
16. Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma.
Thompson EM; Kang KD; Stevenson K; Zhang H; Gromeier M; Ashley D; Brown M; Friedman GK
Transl Oncol; 2024 Feb; 40():101875. PubMed ID: 38183802
[TBL] [Abstract][Full Text] [Related]
17. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
18. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.
Goetz C; Gromeier M
Cytokine Growth Factor Rev; 2010; 21(2-3):197-203. PubMed ID: 20299272
[TBL] [Abstract][Full Text] [Related]
19. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Gromeier M; Brown MC; Zhang G; Lin X; Chen Y; Wei Z; Beaubier N; Yan H; He Y; Desjardins A; Herndon JE; Varn FS; Verhaak RG; Zhao J; Bolognesi DP; Friedman AH; Friedman HS; McSherry F; Muscat AM; Lipp ES; Nair SK; Khasraw M; Peters KB; Randazzo D; Sampson JH; McLendon RE; Bigner DD; Ashley DM
Nat Commun; 2021 Jan; 12(1):352. PubMed ID: 33441554
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
